|Mr. Thomas Meier||CEO, COO & Chairman of Group Executive Board||535k||N/A||1968|
|Mr. Alain Schaffter||Chief Financial Officer||N/A||N/A||1977|
|Mr. Michael Suter||Vice President of Global Accounting||N/A||N/A||N/A|
|Dr. Gunther Loidl||Chief Technology Officer||N/A||N/A||1970|
|Mr. Achim Pluckebaum||Chief Information Officer||N/A||N/A||N/A|
|Dr. Daniel Grotzky||Head of Group Communications||N/A||N/A||N/A|
|Viviane Minden||Chief Human Resources Officer||N/A||N/A||N/A|
|Dr. Anne-Kathrin Stoller Ph.D.||Chief Operating Officer of Bachem Americas, Inc.||N/A||N/A||1974|
|Dr. Torsten Wohr||Chief Commercial Officer||N/A||N/A||1968|
|Mr. Boris Corpataux||VP & Head Global Strategic Alliances||N/A||N/A||N/A|
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
Bachem Holding AG’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 6; Compensation: 7.